Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy

Access Protocol ◽

Early Access ◽

Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5061 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5061-5061

Author(s):

Cora N. Sternberg ◽

Gedske Daugaard ◽

Lajos Geczi ◽

Sebastien J. Hotte ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Open Label ◽

Access Protocol ◽

Early Access ◽

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70417-6 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1263-1268 ◽

Cited By ~ 30

Author(s):

Cora N Sternberg ◽

Daniel Castellano ◽

Gedske Daugaard ◽

Lajos Géczi ◽

Sebastien J Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Open Label ◽

Access Protocol ◽

Early Access ◽

557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

European Urology Supplements ◽

10.1016/s1569-9056(15)60550-4 ◽

2015 ◽

Vol 14 (2) ◽

pp. e557-e557a

Author(s):

D. Castellano ◽

S. Bracarda ◽

M. Tucci ◽

O. Capoun ◽

V. Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Access Protocol ◽

Early Access ◽

Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)

European Urology Supplements ◽

10.1016/s1569-9056(17)30124-0 ◽

2017 ◽

Vol 16 (3) ◽

pp. e93-e94 ◽

Cited By ~ 3

Author(s):

F. Saad ◽

D. Heinrich ◽

S. Gillessen ◽

J. O’Sullivan ◽

J. Carles ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Early Access ◽

Castration Resistant ◽

Radium 223 ◽

Concurrent Use ◽

Access Program

Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemotherapy – results in Czech Republic

European Urology Supplements ◽

10.1016/s1569-9056(16)30243-3 ◽

2016 ◽

Vol 15 (11) ◽

pp. e1394

Author(s):

T. Hradec ◽

O. Capoun ◽

R. Sobotka ◽

M. Pesl ◽

V. Soukup ◽

...

Keyword(s):

Prostate Cancer ◽

Czech Republic ◽

Abiraterone Acetate ◽

Access Protocol ◽

Expanded Access ◽

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Current Pharmaceutical Analysis ◽

10.2174/1573412913666170213152002 ◽

2018 ◽

Vol 14 (3) ◽

pp. 233-238 ◽

Cited By ~ 1

Author(s):

Juana Rodriguez ◽

Gregorio Castaneda ◽

Isabel Lizcano ◽

Jose C. Villa

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Fluorescence Method ◽

Serum Samples ◽

Castration Resistant ◽

Urine And Serum

Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2021.1888704 ◽

2021 ◽

Vol 37 (4) ◽

pp. 635-642

Author(s):

Stephen J. Freedland ◽

Sophia Li ◽

Dominic Pilon ◽

Rachel H. Bhak ◽

Sahil Narkhede ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Psa Progression